Voss Capital’s Eiger BioPharmaceuticals, Inc. EIGR Stock Holding History

Voss Capital’s Portfolio EIGR Stock Details EIGR Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2020 Q4	–	Sell	-582	Closed	-$142K	–	57
2020 Q3	$142K	Sell	582 -3,881	-87%	-$1.21M	0.08%	48
2020 Q2	$1.28M	Buy	4,463 +613	+16%	+$181K	0.86%	25
2020 Q1	$593K	Buy	+3,850	New	+$1.23M	0.79%	21

Other funds holding EIGR

Ameriprise Minneapolis, Minnesota $432B AUM 30.22% 1-Year Est. Return

6CM

683 Capital Management New York $1.92B AUM 85.52% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vivo Capital Palo Alto, California $1.2B AUM 911.44% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return

IVM

InterWest Venture Management San Francisco, California $20.6M AUM 48.5% 1-Year Est. Return

KCM

Knoll Capital Management Miami, Florida $180M AUM 66.11% 1-Year Est. Return

Assenagon Asset Management Senningerberg, Luxembourg $80.2B AUM 50.57% 1-Year Est. Return

Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return

Voss Capital's EIGR Position: Q4 2020 in Review

Voss Capital sold out of Eiger BioPharmaceuticals, Inc. (EIGR) in Q4 2020, closing a stake of 582 shares — an estimated $142K sold.

Voss Capital first reported a position in EIGR in Q1 2020 and held it in 3 quarters. The position peaked at $1.28M in Q2 2020. 91 funds tracked by Wall St. Rank hold EIGR as of Q4 2020.

Voss Capital reported no remaining Eiger BioPharmaceuticals, Inc. position as of Q4 2020 after selling out during the quarter.
Voss Capital sold 582 Eiger BioPharmaceuticals, Inc. shares in Q4 2020, an estimated $142K.
Voss Capital first reported a position in Eiger BioPharmaceuticals, Inc. in Q1 2020 and held it in 3 quarters.
Voss Capital's Eiger BioPharmaceuticals, Inc. position peaked at $1.28M in Q2 2020.
91 funds tracked by Wall St. Rank held Eiger BioPharmaceuticals, Inc. as of Q4 2020.

Based on Voss Capital's 13F filing for Q4 2020, filed 12 Feb 2021.